Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells.
Bromodomain-containing protein 4
Cytokine induction
Gene regulation
Interleukin-34
JQ1
Tumor cell biology
Tumor promotor
Journal
Inflammation and regeneration
ISSN: 1880-9693
Titre abrégé: Inflamm Regen
Pays: England
ID NLM: 101479577
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
11
2019
accepted:
30
06
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
Interleukin (IL)-34 acts as an alternative ligand for the colony-stimulating factor-1 receptor and controls the biology of myeloid cells, including survival, proliferation, and differentiation. IL-34 has been reported to be expressed in cancer cells and to promote tumor progression and metastasis of certain cancers via the promotion of angiogenesis and immunosuppressive macrophage differentiation. We have shown in our previous reports that targeting IL-34 in chemo-resistant tumors in vitro resulted in a remarkable inhibition of tumor growth. Also, we reported poor prognosis in patients with IL-34-expressing tumor. Therefore, blocking of IL-34 is considered as a promising therapeutic strategy to suppress tumor progression. However, the molecular mechanisms that control IL-34 production are still largely unknown. IL-34 producing ovarian cancer cell line HM-1 was treated by bromodomain and extra terminal inhibitor JQ1. The mRNA and protein expression of IL-34 was evaluated after JQ1 treatment. Chromatin immunoprecipitation was performed to confirm the involvement of bromodomain-containing protein 4 (Brd4) in the regulation of the We identified Brd4 as one of the critical molecules that regulate The results unveiled for the first time the responsible molecule Brd4 that regulates
Sections du résumé
BACKGROUND
BACKGROUND
Interleukin (IL)-34 acts as an alternative ligand for the colony-stimulating factor-1 receptor and controls the biology of myeloid cells, including survival, proliferation, and differentiation. IL-34 has been reported to be expressed in cancer cells and to promote tumor progression and metastasis of certain cancers via the promotion of angiogenesis and immunosuppressive macrophage differentiation. We have shown in our previous reports that targeting IL-34 in chemo-resistant tumors in vitro resulted in a remarkable inhibition of tumor growth. Also, we reported poor prognosis in patients with IL-34-expressing tumor. Therefore, blocking of IL-34 is considered as a promising therapeutic strategy to suppress tumor progression. However, the molecular mechanisms that control IL-34 production are still largely unknown.
METHODS
METHODS
IL-34 producing ovarian cancer cell line HM-1 was treated by bromodomain and extra terminal inhibitor JQ1. The mRNA and protein expression of IL-34 was evaluated after JQ1 treatment. Chromatin immunoprecipitation was performed to confirm the involvement of bromodomain-containing protein 4 (Brd4) in the regulation of the
RESULTS
RESULTS
We identified Brd4 as one of the critical molecules that regulate
CONCLUSION
CONCLUSIONS
The results unveiled for the first time the responsible molecule Brd4 that regulates
Identifiants
pubmed: 33072227
doi: 10.1186/s41232-020-00129-4
pii: 129
pmc: PMC7556959
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Nat Rev Cancer. 2012 Jun 22;12(7):465-77
pubmed: 22722403
Biochim Biophys Acta. 2014 Apr;1845(2):182-201
pubmed: 24440852
Mol Cell. 2004 Jan 16;13(1):33-43
pubmed: 14731392
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Sci Rep. 2018 Jan 11;8(1):418
pubmed: 29323162
JCI Insight. 2018 Jul 26;3(14):
pubmed: 30046005
Nature. 2010 Dec 23;468(7327):1119-23
pubmed: 21068722
Inflamm Regen. 2018 Mar 5;38:3
pubmed: 29515691
Science. 2008 May 9;320(5877):807-11
pubmed: 18467591
J Biol Chem. 2016 Dec 23;291(52):26647-26657
pubmed: 27821592
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Cancer Res. 2014 Dec 1;74(23):7090-102
pubmed: 25277525
Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5360-5365
pubmed: 31298388
Nucleic Acids Res. 2019 Jan 8;47(D1):D745-D751
pubmed: 30407521
Cell Death Differ. 2015 Feb;22(2):237-46
pubmed: 25190142
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Jpn J Cancer Res. 1989 May;80(5):459-63
pubmed: 2502522
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050
pubmed: 29632196
Int J Mol Sci. 2016 Nov 07;17(11):
pubmed: 27827996
J Hematol Oncol. 2019 Jul 16;12(1):77
pubmed: 31311566
J Immunol. 2013 Apr 1;190(7):3670-8
pubmed: 23420887
Cancer Res. 2016 Oct 15;76(20):6030-6042
pubmed: 27550451
N Engl J Med. 2012 Aug 16;367(7):647-57
pubmed: 22894577
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
J Leukoc Biol. 2018 Nov;104(5):931-951
pubmed: 30066957
Oncotarget. 2017 Dec 15;9(3):3432-3445
pubmed: 29423057
Int J Cancer. 2016 Nov 1;139(9):2047-55
pubmed: 27388964
Nucleic Acids Res. 2016 Jan 4;44(D1):D164-71
pubmed: 26438538
Mol Cancer Ther. 2014 May;13(5):1142-54
pubmed: 24435446
Nat Rev Drug Discov. 2019 Aug;18(8):609-628
pubmed: 31273347
Expert Opin Ther Pat. 2014 Feb;24(2):185-99
pubmed: 24261714
Database (Oxford). 2018 Jan 1;2018:
pubmed: 30576484
Nucleic Acids Res. 2010 Jan;38(Database issue):D492-6
pubmed: 19854944
Curr Opin Oncol. 2013 Nov;25(6):637-45
pubmed: 24076584
Sci Rep. 2018 Jul 10;8(1):10410
pubmed: 29991720
Sci Rep. 2016 Jul 01;6:28814
pubmed: 27363523
Nucleic Acids Res. 2019 Jul 2;47(W1):W248-W255
pubmed: 31028388
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Mol Pharmacol. 2017 Dec;92(6):694-706
pubmed: 28974538